Want to see AU:IMC full AI Analyst Report?
Top Page
Immuron Limited
(Sydney:IMC)
Select Model
Select Model
Rating:52Neutral
Price Target:
AU$0.04
▲(7.50% Upside)
Action:Reiterated
Date:07/07/26
The score is held back primarily by weak financial performance—ongoing losses and negative operating/free cash flow outweigh the benefit of revenue growth and low leverage. Technicals are moderately supportive with price above key short- and mid-term moving averages and positive MACD, but longer-term trend and elevated stochastic temper the signal. Valuation is constrained by a negative P/E and no stated dividend yield.
Positive Factors
Differentiated product platform
Immuron’s oral antibody-based hyperimmune colostrum platform addresses gastrointestinal and infectious-disease indications with both marketed and pipeline assets. A platform approach and oral delivery create durable commercial optionality, repeat purchase potential, and modular R&D advantages that support multi-product scaling over months.
Negative Factors
Sustained unprofitability
Persistent negative net profit and EBIT margins erode equity and constrain internal funding for trials and commercialization. Without structural margin improvement through scale, pricing or cost cuts, continued losses will necessitate external financing, increasing dilution risk and challenging long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated product platform
Immuron’s oral antibody-based hyperimmune colostrum platform addresses gastrointestinal and infectious-disease indications with both marketed and pipeline assets. A platform approach and oral delivery create durable commercial optionality, repeat purchase potential, and modular R&D advantages that support multi-product scaling over months.
Read all positive factors
Immuron Limited (IMC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$13.88M
Dividend YieldN/A
Average Volume (3M)862.36K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue Growth14.30%
EPS Growth41.93%
CountryAU
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding322,848,080
10 Day Avg. Volume372,599
30 Day Avg. Volume862,359
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.75
Price to Sales (P/S)1.93
P/FCF Ratio-2.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$8.98M
Immuron Limited Business Overview & Revenue Model
Company Description
Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies. Operating across two divisions—Research and...
How the Company Makes Money
Immuron makes money primarily through (1) product sales from its commercial offerings of orally administered hyperimmune colostrum-based products (where available), and (2) funding and payments associated with research, development, and commercial...
Immuron Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.48M | 7.29M | 4.90M | 1.80M | 765.19K | 145.78K |
| Gross Profit | 4.76M | 4.77M | 3.34M | 1.31M | 523.50K | 94.70K |
| EBITDA | -5.08M | -5.31M | -6.19M | -3.80M | -3.08M | -8.33M |
| Net Income | -4.65M | -5.22M | -6.94M | -3.79M | -2.85M | -8.38M |
Balance Sheet | ||||||
| Total Assets | 15.14M | 10.13M | 15.55M | 21.99M | 24.86M | 27.05M |
| Cash, Cash Equivalents and Short-Term Investments | 10.00M | 5.87M | 11.66M | 18.99M | 22.11M | 25.05M |
| Total Debt | 0.00 | 117.13K | 173.50K | 189.09K | 209.79K | 20.50K |
| Total Liabilities | 2.06M | 2.06M | 2.84M | 2.37M | 1.68M | 1.16M |
| Stockholders Equity | 13.08M | 8.07M | 12.71M | 19.62M | 23.18M | 25.90M |
Cash Flow | ||||||
| Free Cash Flow | -4.62M | -6.14M | -5.56M | -2.50M | -3.14M | -4.09M |
| Operating Cash Flow | -4.62M | -6.14M | -5.56M | -2.49M | -3.13M | -4.08M |
| Investing Cash Flow | -4.75K | -2.90M | 327.56K | -2.74M | 11.74K | 2.57K |
| Financing Cash Flow | 6.97M | 199.75K | 829.00 | -35.02K | -36.26K | 26.49M |
Immuron Limited Technical Analysis
Positive
0.04
Price Trends
0.04
Positive
0.03
Positive
0.04
Negative
Market Momentum
<0.01
Negative
65.82
Neutral
90.48
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMC, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 65.82 is Neutral, neither overbought nor oversold. The STOCH value of 90.48 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IMC.
Immuron Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | AU$21.17M | 7.83 | 10.35% | 2.81% | -18.17% | -70.18% | |
54 Neutral | AU$77.27M | -15.71 | -258.19% | ― | 9.28% | -40.00% | |
53 Neutral | AU$57.57M | 60.47 | 17.85% | ― | 38.44% | 230.77% | |
52 Neutral | AU$13.88M | -2.30 | -43.95% | ― | 14.30% | 41.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$18.63M | -2.23 | -183.51% | ― | ― | -59.29% | |
40 Underperform | AU$3.16M | -2.50 | -109.45% | ― | ― | 43.14% |
* Healthcare Sector Average
AU:IMC
Immuron Limited
0.04
-0.02
-33.85%
AU:AVE
Avecho Biotechnology Limited
0.02
0.01
120.00%
AU:ANR
Anatara Lifesciences Ltd
0.01
0.00
0.00%
AU:AGN
Argenica Therapeutics Ltd
0.14
-0.57
-80.28%
AU:EZZ
EZZ Life Science Holdings Ltd.
0.48
-1.71
-78.09%
AU:BIO
Biome Australia Ltd
0.26
-0.29
-52.73%
Immuron Limited Corporate Events
Immuron Seeks Transformational Partnership for C. difficile Drug IMM-529
Jul 5, 2026
Immuron Limited has engaged life sciences advisory firm Pullan Consulting to secure a strategic partner for its Clostridioides difficile infection candidate IMM-529, which holds U.S. FDA Investigational New Drug approval for a Phase 2 trial. The m...
Immuron Adjusts Capital Structure as Over 3.8 Million Shares Cease
Jun 29, 2026
Immuron Limited has notified the market of the cessation of 3,805,528 ordinary fully paid shares, as disclosed in an Appendix 3H filing to the ASX. The cessation of these securities alters the company’s issued capital structure, which may af...
Immuron Options Lapse, Trimming Potential Dilution in Capital Structure
Jun 18, 2026
Immuron Limited has notified the market that 1,430,000 listed options, identified under the ASX code IMCAI and carrying various expiry dates and exercise prices, have lapsed unexercised. The expiry of these options reduces the company’s outs...
Immuron Says No Undisclosed News Behind Share Price Spike
May 28, 2026
Immuron Limited has responded to an ASX price query after its shares rose from A$0.032 to A$0.044 on increased trading volume. The company said it is not aware of any undisclosed information that could explain the recent trading activity in its se...
Immuron CEO to Spotlight Antibody-Based GI Portfolio at Emerging Growth Conference
Apr 30, 2026
Immuron Limited said chief executive Steven Lydeamore will deliver a virtual presentation at the Emerging Growth Conference on May 7, 2026, giving investors and stakeholders an opportunity to hear directly from management. The appearance underscor...
Immuron Posts Double-Digit Q3 Sales Growth on Rising Travelan Demand
Apr 16, 2026
Immuron reported unaudited global third-quarter sales of AUD$1.5 million, a 16% rise on the prior comparative period, with year-to-date sales to March 2026 up 7% to AUD$5.7 million. Growth was driven by strong performance of Travelan in Australia,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.